No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Jasper Therapeutics, Inc. (JSPR) stock was $0.59 as of Oct 6, 2026, 9:59 AM EDT, down 0.83% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -76.0% · 3-year avg -57.6%/yr · 5-year avg -62.5%/yr
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
Biotechnology · Redwood City, CA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.08
Revenue Est.
$12.00M
Last Quarter Results
EPS
$-0.10
vs Estimate
$-0.27
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1JSPR | $9.55M | $0.59 | -0.83% | -76.03% | -62.51% | N/A | N/A |
| 2AIMD | $9.57M | $1.30 | -2.26% | -62.15% | -58.50% | N/A | vs JSPR |
| 3ICU | $9.22M | $3.25 | -8.45% | -45.14% | N/A | N/A | vs JSPR |
| 4ADVB | $9.18M | $6.64 | +4.73% | -31.85% | N/A | N/A | vs JSPR |
| 5MDCX | $10.43M | $0.17 | -1.14% | -93.34% | N/A | N/A | vs JSPR |
| 6HCTI | $8.65M | $0.58 | -4.78% | -99.61% | N/A | N/A | vs JSPR |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$20.00
+3301.9% upside
Low
$20.00
Current
$0.59
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.32 | $-0.08 | $0.16 | 1 |
| Quarter ending Dec 2026 | $-0.46 | $-0.44 | $-0.42 | 1 |
| Quarter ending Mar 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Quarter ending Jun 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.22 | $-0.89 | $-0.54 | 1 |
| FY 2027 | $-1.92 | $-1.07 | $-0.21 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $12.00M | $12.00M | $12.00M | 3 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $12.00M | $12.00M | $12.00M | 1 |
| FY 2027 | $173800.00 | $173800.00 | $173800.00 | 1 |
